tirzepatide vs survodutide
updated
tirzepatide (tier S) vs survodutide (tier A): what each is, half-life and source counts side by side.
tirzepatide · tier S
A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.
tier rationale
Tirzepatide is in S tier because large randomized trials have shown weight loss, improved blood-sugar control and reduced sleep-apnea severity. Zepbound and Mounjaro have US approvals for these uses.
survodutide · tier A
Investigational GLP-1/glucagon dual agonist. In a phase 3 obesity trial, mean weight loss was 13.0% versus 5.4% with placebo at 76 weeks. Separate trials studied MASH and liver fibrosis.
tier rationale
survodutide has a published phase 3 obesity result (SYNCHRONIZE-1: about 16.6% weight loss over 76 weeks) and a phase 2 MASH signal strong enough to earn FDA Breakthrough Therapy designation. that is real, late-stage clinical evidence, which puts it firmly in A territory. it lands below retatrutide (S, deeper phase 3 weight loss) because the obesity number is more modest and it remains investigational with no approval and confirmatory MASH outcomes still years out. graded on merit: strong data, narrow no-label status.
at a glance
| tirzepatide | survodutide | |
|---|---|---|
| tier | S | A |
| category | weight loss | weight loss |
| sources | 20 | 5 |
| claims evaluated | n/a | 7 |
| half-life | ~5 days | ~6 days |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.